PSEN2 and Alzheimer disease: Most AD patients (~98%) have late-onset sporadic AD; however, most animal models currently used to develop AD therapies are based on familial AD mutations in APP, PSEN1 or PSEN2. Although AD has multiple causes, the human apolipoprotein E4 allele (ApoE4) is the strongest genetic risk factor.